A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
AssigneeAnavex Life Sciences Corp.
InventorsChristopher U. Missling, Cameron Durrant
Life of this patent
Estimating the term…
Abstract
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with any therapeutically effective amount of an AED.
Claims20
A method of treating seizures in a subject in need of such treatment comprising administering a therapeutically effective amount of 1-(2,2-diphenyltetrahydrofuran-3-yl)-N-methylmethanamine or a pharmaceutically acceptable salt thereof;
- and administering at least one anti-epilepsy drug (AED), wherein the therapeutically effective amount is the amount to elicit pharmacological response of reduction in the daily number of seizures by at least 50%.
A method of treating seizures in a subject in need of such treatment comprising administering to the subject a low dose donepezil in conjunction with a therapeutic effective amount of 1-(2,2-diphenyltetrahydrofuran-3-yl)-N-methylmethanamine, or a pharmaceutically acceptable salt thereof;
- wherein the therapeutic effective amount is 0.5-10 mg/day, wherein the therapeutically effective amount is the amount to elicit pharmacological response of reduction in the daily number of seizures by at least 50%.
Dependencies are inferred from the claim text.